FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Eberhard Schleyer

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Half-Life

Phenomena

Metabolic Clearance Rate

Co-author Network

Publications

TOP 3
Christoph Röllig; Eberhard Schleyer; Hubert Serve; Shabnam Shaid; Carsten Müller-Tidow; Karl-Heinz Pflüger; Barbara Ritter; Wolfgang E Berdel; Christian Brandts; Gerhard Ehninger; Martina Haibach; Marcus Hentrich; Christian Junghanß; Alwin Krämer; Michael Kramer; Stefan W Krause
Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia.
Thomas Illmer; Hans-M Thiede; Christian Thiede; Martin Bornhäuser; Markus Schaich; Eberhard Schleyer; Gerhard Ehninger
A highly sensitive method for the detection of PKC412 (CGP41251) and its metabolites by high-performance liquid chromatography.
F Fierro; Thomas Illmer; D Jing; Eberhard Schleyer; Gerhard Ehninger; Sabine Boxberger; Martin Bornhäuser
Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Eberhard Schleyer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Christoph Röllig; Eberhard Schleyer; Hubert Serve; Shabnam Shaid; Carsten Müller-Tidow; Karl-Heinz Pflüger; Barbara Ritter; Wolfgang E Berdel; Christian Brandts; Gerhard Ehninger; Martina Haibach; Marcus Hentrich; Christian Junghanß; Alwin Krämer; Michael Kramer; Stefan W Krause
Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia.
Leukemia & lymphoma 2012;53(6):1062-7.
2007: Thomas Illmer; Hans-M Thiede; Christian Thiede; Martin Bornhäuser; Markus Schaich; Eberhard Schleyer; Gerhard Ehninger
A highly sensitive method for the detection of PKC412 (CGP41251) and its metabolites by high-performance liquid chromatography.
Journal of pharmacological and toxicological methods 2007;56(1):23-7.
2007: F Fierro; Thomas Illmer; D Jing; Eberhard Schleyer; Gerhard Ehninger; Sabine Boxberger; Martin Bornhäuser
Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro.
Cell proliferation 2007;40(3):355-66.
2007: Stefan Pursche; Oliver G Ottmann; Gerhard Ehninger; Eberhard Schleyer
High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;852(1-2):208-16.
2007: M Bonin; Stefan Pursche; T Bergeman; Traugott Leopold; Thomas Illmer; Gerhard Ehninger; Eberhard Schleyer; Martin Bornhauser
F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.
Bone marrow transplantation 2007;39(4):201-6.
2005: Martin Bornhäuser; Stefan Pursche; Malte Bonin; Jens Freiberg-Richter; Andreas Jenke; Thomas Illmer; Gerhard Ehninger; Eberhard Schleyer
Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3855-6; author reply 3857-8.
2005: Andreas Jenke; Jens Freiberg-Richter; C Johne; H Knoth; Eberhard Schleyer; Gerhard Ehninger; Martin Bornhäuser
Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation.
Bone marrow transplantation 2005;35(6):627-8.
2005: Uwe Platzbecker; M Haase; R Herbst; Annette Hänel; K Voigtmann; Christian Thiede; Brigitte Mohr; Eberhard Schleyer; Traugott Leopold; Matthias Orth; Mathias Hänel; Gerhard Ehninger; Martin Bornhäuser
Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.
British journal of haematology 2005;128(5):625-30.
2005: Andreas Jenke; Jens Freiberg-Richter; S Wilhelm; M Freund; Ulf Renner; Martin Bornhäuser; Eberhard Schleyer; Gerhard Ehninger; Ulrich Schuler
Accidental busulfan overdose during conditioning for stem cell transplantation.
Bone marrow transplantation 2005;35(2):125-8.
2004: Andreas Jenke; Ulf Renner; Ulrich Schuler; Sylvia Wauer; Traugott Leopold; Eberhard Schleyer; Gerhard Ehninger
Improved assay for determination of busulfan by liquid chromatography using postcolumn photolysis.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;805(1):147-53.
2004: Martin Bornhauser; Andreas Jenke; Jens Freiberg-Richter; Jörgen Radke; Ulrich Schuler; Brigitte Mohr; Gerhard Ehninger; Eberhard Schleyer
CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Annals of hematology 2004;83(6):401-2.
2004: Philipp le Coutre; Karl-Anton Kreuzer; Stefan Pursche; Malte v Bonin; Traugott Leopold; Gökben Baskaynak; Bernd Dörken; Gerhard Ehninger; Oliver G Ottmann; Andreas Jenke; Martin Bornhäuser; Eberhard Schleyer
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.
Cancer chemotherapy and pharmacology 2004;53(4):313-23.
2004: Thomas Illmer; Markus Schaich; Uwe Platzbecker; Jens Freiberg-Richter; U Oelschlägel; M von Bonin; Stefan Pursche; T Bergemann; Gerhard Ehninger; Eberhard Schleyer
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.
Leukemia 2004;18(3):401-8.
2004: Eberhard Schleyer; Stefan Pursche; Claus-Henning Köhne; Ulrich Schuler; Ulf Renner; Harald Gschaidmeier; Jens Freiberg-Richter; Traugott Leopold; Andreas Jenke; M Bonin; T Bergemann; Philipp le Coutre; M Gruner; Martin Bornhäuser; Oliver G Ottmann; Gerhard Ehninger
Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;799(1):23-36.
2004: Martin Bornhäuser; Thomas Illmer; Philipp le Coutre; J Pursche; M von Bonin; Jens Freiberg-Richter; Markus Schaich; Uwe Platzbecker; Christian Thiede; Oliver G Ottmann; Ch Köhne; Jan Braess; Gerhard Ehninger; Eberhard Schleyer
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells.
Annals of hematology 2004;83 Suppl 1():S61-4.
2004: Frank Kroschinsky; Eberhard Schleyer; Ulf Renner; Claudia Schimming; Christoph Schimmelpfennig; Martin Bornhäuser; Thomas Illmer; Lorenz Trümper; Gerhard Ehninger; Markus Schaich
Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
Cancer chemotherapy and pharmacology 2004;53(1):61-7.
2003: Heike Pfeifer; Barbara Wassmann; Wolf-Karsten Hofmann; Martina Komor; Urban J Scheuring; Patrick Brück; Anja Binckebanck; Eberhard Schleyer; Nicola Gökbuget; Thomas Wolff; Michael Lübbert; Lothar Leimer; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4674-81.
2003: Martin Bornhauser; Barry Storer; John T Slattery; Frederick R Appelbaum; H Joachim Deeg; John Hansen; Paul J Martin; George B McDonald; W Garrett Nichols; Jerald P Radich; Ann Woolfrey; Andreas Jenke; Eberhard Schleyer; Christian Thiede; Gerhard Ehninger; Claudio Anasetti
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
Blood 2003;102(3):820-6.
2003: Barbara Wassmann; Urban J Scheuring; Christian Thiede; Heike Pfeifer; Martin Bornhäuser; F Griesinger; Andreas Hochhaus; Eberhard Schleyer; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Bone marrow transplantation 2003;31(7):611-4.
2003: Alexander Kiani; Claus-Henning Köhne; Thorsten Franz; Jens Passauer; Thorsten Haufe; Peter Gross; Gerhard Ehninger; Eberhard Schleyer
Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.
Cancer chemotherapy and pharmacology 2003;51(3):266-70.
2002: Wolfgang Kern; Jan Braess; Marion Kotschofsky; Stefan Samel; Heinz Becker; Wolfgang Hiddemann; Eberhard Schleyer
Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
Anticancer research 2002;22(5):3099-102.
2001: Wolfgang Kern; Eberhard Schleyer; Jan Braess; E Wittmer; J Ohnesorge; Michael Unterhalt; B Wörmann; T Büchner; Wolfgang Hiddemann
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Annals of hematology 2001;80(6):334-9.
2001: Jan Braess; G Jahns-Streubel; Claudia Schoch; Detlef Haase; Torsten Haferlach; Michael Fiegl; S Voss; Wolfgang Kern; Eberhard Schleyer; Wolfgang Hiddemann
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.
British journal of haematology 2001;113(4):975-82.
2001: W Kern; Eberhard Schleyer; M Bergmann; Harald Gschaidmeier; G Ehninger; W Hiddemann; Jan Braess
Detection and separation of the S-adenosylmethionine-decarboxylase inhibitor SAM486A in human plasma and urine by reversed-phase ion-pairing high-performance liquid chromatography.
Journal of pharmacological and toxicological methods 2001;45(3):175-80.
2001: Wolfgang Kern; Jan Braess; S Friedrichsen; Cornelia C Kaufmann; Eberhard Schleyer; Wolfgang Hiddemann
Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve.
Journal of cancer research and clinical oncology 2001;127(1):64-8.
2000: Wolfgang Kern; Jan Braess; Cornelia C Kaufmann; S Wilde; Eberhard Schleyer; Wolfgang Hiddemann
Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.
Anticancer research 2000;20(5C):3679-88.
2000: Jan Braess; S Voss; G Jahns-Streubel; Claudia Schoch; Torsten Haferlach; Wolfgang Kern; S Keye; Eberhard Schleyer; Wolfgang Hiddemann
The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
British journal of haematology 2000;110(1):170-9.
2000: Jan Braess; C Wegendt; G Jahns-Streubel; Wolfgang Kern; S Keye; Michael Unterhalt; Eberhard Schleyer; Wolfgang Hiddemann
Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
British journal of haematology 2000;109(2):388-95.
2000: Eberhard Schleyer; K L Rudolph; Jan Braess; M Unterhalt; G Ehninger; W Hiddemann; W Kern
Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid.
Cancer chemotherapy and pharmacology 2000;45(2):165-71.
1999: Jan Braess; J Pförtner; W Kern; W Hiddemann; Eberhard Schleyer
Cytidine deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells.
Annals of hematology 1999;78(11):514-20.
1999: Jan Braess; C Wegendt; Michaela Feuring-Buske; Joachim Riggert; Wolfgang Kern; Wolfgang Hiddemann; Eberhard Schleyer
Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside.
British journal of haematology 1999;105(2):388-93.
1999: Wolfgang Kern; Jan Braess; B Böttger; Cornelia C Kaufmann; Wolfgang Hiddemann; Eberhard Schleyer
Oxaliplatin pharmacokinetics during a four-hour infusion.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):761-5.
1998: Jan Braess; Mathias Freund; A Hanauske; G Heil; C Kaufmann; Wolfgang Kern; M Schüssler; Wolfgang Hiddemann; Eberhard Schleyer
Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
Leukemia 1998;12(10):1618-26.
1998: Wolfgang Kern; Jan Braess; H Bertz; Christiane Pott; Eberhard Schleyer; J Finke; Reinhard Rüchel; Wolfgang Hiddemann
Chronic systemic aspergillosis in a patient with acute myeloid leukemia.
Annals of hematology 1998;76(3-4):175-7.
1997: Dinko Berkovic; Eduard A M Fleer; J Breass; J Pförtner; Eberhard Schleyer; Wolfgang Hiddemann
The influence of 1-beta-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells.
Leukemia 1997;11(12):2079-86.
1997: Eberhard Schleyer; S Kühn; H Rührs; Michael Unterhalt; Cornelia C Kaufmann; Wolfgang Kern; Jan Braess; G Sträubel; Wolfgang Hiddemann
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Leukemia 1997;11 Suppl 5():S15-21.
1997: G Jahns-Streubel; C Reuter; U Auf der Landwehr; Michael Unterhalt; Eberhard Schleyer; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia.
Blood 1997;90(5):1968-76.
1997: Tobias J. Legler; I Fischer; J Dittmann; G Simson; Rainer Lynen; Andreas Humpe; Joachim Riggert; Eberhard Schleyer; Wolfgang Kern; Wolfgang Hiddemann; Michael Köhler
Frequency and causes of refractoriness in multiply transfused patients.
Annals of hematology 1997;74(4):185-9.
1997: C Reuter; Eberhard Schleyer; C Rolf; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts.
Leukemia 1997;11(4):561-71.
1997: Wolfgang Kern; Eberhard Schleyer; Michael Unterhalt; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Cancer 1997;79(1):59-68.
1996: Jan Braess; Wolfgang Kern; Michael Unterhalt; Cornelia C Kaufmann; B Ramsauer; M Schüssler; A Kaeser-Fröhlich; Wolfgang Hiddemann; Eberhard Schleyer
Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone.
Annals of hematology 1996;73(4):201-4.
1996: Wolfgang Hiddemann; Eberhard Schleyer; Michael Unterhalt; Wolfgang Kern; Thomas Büchner
Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
Therapeutic drug monitoring 1996;18(4):341-9.
1996: Eberhard Schleyer; S Kühn; H Rührs; Michael Unterhalt; Cornelia C Kaufmann; Wolfgang Kern; Jan Braess; G Sträubel; Wolfgang Hiddemann
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Leukemia 1996;10(4):707-12.
1996: Jan Braess; J Pförtner; Cornelia C Kaufmann; B Ramsauer; Michael Unterhalt; Wolfgang Hiddemann; Eberhard Schleyer
Detection and determination of the major metabolites of [3H]cytosine arabinoside by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;676(1):131-40.
1995: I Gralow; W F von Hornstein; Eberhard Schleyer; Wolfgang Hiddemann
[Pharmacokinetics of buprenorphine in subcutaneous administration].
Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS 1995;30(7):412-6.
1995: G Jahns-Streubel; C Reuter; Michael Unterhalt; Eberhard Schleyer; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
Leukemia 1995;9(11):1857-63.
1995: Eberhard Schleyer; J Reinhardt; Michael Unterhalt; Wolfgang Hiddemann
Highly sensitive coupled-column high-performance liquid chromatographic method for the separation and quantitation of the diastereomers of leucovorin and 5-methyltetrahydrofolate in serum and urine.
Journal of chromatography. B, Biomedical applications 1995;669(2):319-30.
1995: Eberhard Schleyer; Jan Braess; B Ramsauer; Michael Unterhalt; C Kaufmann; S Wilde; M Schüssler; Wolfgang Hiddemann
Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
Leukemia 1995;9(6):1085-90.
1995: I Gralow; W F von Hornstein; Eberhard Schleyer; Wolfgang Hiddemann
[Continuous subcutaneous buprenorphine application in the treatment of cancer pain.].
Schmerz (Berlin, Germany) 1995;9(3):117-23.
1995: B Ramsauer; Jan Braess; Michael Unterhalt; Cornelia C Kaufmann; Wolfgang Hiddemann; Eberhard Schleyer
Highly sensitive high-performance liquid chromatographic assay for 1-beta-D-arabinofuranosylcytosine-5'-stearyl phosphate (cytarabine-ocfosfate).
Journal of chromatography. B, Biomedical applications 1995;665(1):183-92.
1994: Wolfgang Hiddemann; Bernhard Wörmann; C Reuter; Eberhard Schleyer; Michael Zühlsdorf; A Böckmann; Thomas Büchner
New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
Seminars in oncology 1994;21(6 Suppl 16):33-8.
1994: Eberhard Schleyer; A Kamischke; Cornelia C Kaufmann; Michael Unterhalt; Wolfgang Hiddemann
New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites.
Leukemia 1994;8(3):435-40.
1994: C Reuter; U Auf der Landwehr; Eberhard Schleyer; Michael Zühlsdorf; C Ameling; C Rolf; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
Leukemia 1994;8(2):217-25.
1993: Eberhard Schleyer; R Lohmann; C Rolf; A Gralow; Cornelia C Kaufmann; Michael Unterhalt; Wolfgang Hiddemann
Column-switching solid-phase trace-enrichment high-performance liquid chromatographic method for measurement of buprenorphine and norbuprenorphine in human plasma and urine by electrochemical detection.
Journal of chromatography 1993;614(2):275-83.
1992: Wolfgang Hiddemann; Eberhard Schleyer; Michael Unterhalt; Michael Zühlsdorf; C Rolf; C Reuter; U Kewer; C Uhrmeister; Bernhard Wörmann; Thomas Büchner
Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Leukemia 1992;6(12):1273-80.
1992: Gerhard Ehninger; B Proksch; T Wanner; Ulrich Schuler; F W Busch; H Schmidt; Eberhard Schleyer; K Jaschonek; Wolfgang Hiddemann
Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
Leukemia 1992;6(6):582-7.
1992: Wolfgang Hiddemann; Michael Kiehl; Michael Zühlsdorf; C Busemann; Eberhard Schleyer; Bernhard Wörmann; Thomas Büchner
Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
Seminars in oncology 1992;19(2 Suppl 4):31-7.
1990: Wolfgang Hiddemann; Eberhard Schleyer; C Uhrmeister; Carlo Aul; Georg Maschmeyer; Achim Heinecke; Thomas Büchner
High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
Cancer treatment reviews 1990;17(2-3):279-85.
1989: Eberhard Schleyer; Gerhard Ehninger; Michael Zühlsdorf; B Proksch; Wolfgang Hiddemann
Detection and separation of intracellular 1-beta-D-arabinofuranosylcytosine-5-triphosphate by ion-pair high-performance liquid chromatography.
Journal of chromatography 1989;497():109-20.